Trial Profile
A Single Centre, Randomised, Placebo-Controlled, Four-Way Cross Over Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Inhaled Doses of GSK233705 and GW642444 as Monotherapies and in Combination in Healthy Japanese Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs Darotropium bromide (Primary) ; Vilanterol (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 11 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.
- 05 Mar 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 05 Mar 2009 Actual end date (Feb 2009) added as reported by ClinicalTrials.gov.